The binding of Miltuximab®-IR800 to GBM cells U-87 was characterized by flow cytometry and found to be comparable to that of unconjugated Miltuximab® (Figure 3, left) confirming retention of GPC-1 binding capacity following conjugation. The gene discussed is GPC1; the disease is glioblastoma.